Accordign to the company, the Arima-HiC sample preparation kit is a simple and rapid 6-hour protocol that enables detection of long-range chromatin interactions that can be used across multiple applications.
This public launch brings to a close a successful Early Access Program that yielded further proof of product performance and valuable feedback from early access customers.
The limited scale of operation of the Early Access Program allowed the company to work closely with customers, leading to an enhanced Arima-HiC offering.
To facilitate data analysis, the company collaborated with academic partners to optimize established open-source tools, including HiCUP and SALSA for Arima-HiC data.
These tools leverage unique aspects of Arima-HiC data, such as greater coverage uniformity and higher long-range signal-to-noise ratio, for improved chromatin conformation and genome assembly analysis.
Such engagement with the open source community will continue to be a key focus for the company as part of its sustained efforts to streamline and expedite the sample-to-results workflow.
The company is also continuing to work with key academic collaborators on targeted Hi-C approaches along with developing workflows for new genomic applications with industry partner Agilent Technologies.
Feedback and data generated by early access customers also played an important role in further validating the Arima-HiC technology. Recently, the first dataset from Phase I of the Vertebrate Genome Project that leveraged Arima-HiC technology was released.
In addition to high-quality genome assemblies, other labs demonstrated the ability to detect chromatin loops and topologically associated domains with high confidence at significantly reduced depth of sequencing compared to other methods.
As part of the company's transition out of early access phase, it has scaled its operations to make the Arima-HiC technology easily accessible to researchers.
In addition to expanding its sales team, it has streamlined its order-to-ship process, and enhanced its customer service and support experience.
Arima Genomics is a biotechnology company that aims to accelerate the understanding of genome sequence and structure and their role in health, disease, and species evolution.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA